MMCM
TEVA icon

Murphy & Mullick Capital Management’s Teva Pharmaceuticals TEVA Stock Holding History

Murphy & Mullick Capital Management’s Portfolio TEVA Stock Details TEVA Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		– Sell
-3
Closed -$94 – 779
2025
Q4 		$94 Buy
+3
New +$74 ﹤0.01% 768
2025
Q3 		– Sell
-33
Closed -$510 – 685
2025
Q2 		$510 Hold
33
– – ﹤0.01% 640
2025
Q1 		$507 Sell
33
-175
-84% -$3.13K ﹤0.01% 631
2024
Q4 		$4.58K Buy
+208
New +$3.78K ﹤0.01% 509

Other funds holding TEVA

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
HIIFS
Harel Insurance Investments & Financial Services Ramat Gan, Israel $20.6B AUM 59.59% 1-Year Est. Return
PF
Phoenix Financial Givatayim, Israel $14.6B AUM 57.48% 1-Year Est. Return
MMH
Menora Mivtachim Holdings Ramat Gan, Israel $25.6B AUM 50.04% 1-Year Est. Return
WCM Investment Management
WCM Investment Management Laguna Beach, California $55.2B AUM 57.07% 1-Year Est. Return
CI
Clal Insurance Tel-Aviv, Israel $22.3B AUM 79.91% 1-Year Est. Return
MIFH
Migdal Insurance & Financial Holdings Petach Tikva, Israel $15.6B AUM 71.29% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
LIM
Lingotto Investment Management London, United Kingdom $4.67B AUM 70.24% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

Murphy & Mullick Capital Management's TEVA Position: Q1 2026 in Review

Murphy & Mullick Capital Management sold out of Teva Pharmaceuticals (TEVA) in Q1 2026, closing a stake of 3 shares — an estimated $94 sold.

Murphy & Mullick Capital Management first reported a position in TEVA in Q4 2024 and held it in 4 quarters. The position peaked at $4.58K in Q4 2024. 651 funds tracked by Wall St. Rank hold TEVA as of Q1 2026.

  • Murphy & Mullick Capital Management reported no remaining Teva Pharmaceuticals position as of Q1 2026 after selling out during the quarter.
  • Murphy & Mullick Capital Management sold 3 Teva Pharmaceuticals shares in Q1 2026, an estimated $94.
  • Murphy & Mullick Capital Management first reported a position in Teva Pharmaceuticals in Q4 2024 and held it in 4 quarters.
  • Murphy & Mullick Capital Management's Teva Pharmaceuticals position peaked at $4.58K in Q4 2024.
  • 651 funds tracked by Wall St. Rank held Teva Pharmaceuticals as of Q1 2026.

Based on Murphy & Mullick Capital Management's 13F filing for Q1 2026, filed 17 Apr 2026.